BNP Paribas Financial Markets’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,077
| Closed | -$75K | – | 4267 |
|
|
2024
Q1 | $75K | Buy |
5,077
+2,043
| +67% | +$28.7K | ﹤0.01% | 3503 |
|
|
2023
Q4 | $40.7K | Buy |
3,034
+1,495
| +97% | +$18.9K | ﹤0.01% | 3597 |
|
|
2023
Q3 | $19K | Sell |
1,539
-1,187
| -44% | -$14.4K | ﹤0.01% | 3570 |
|
|
2023
Q2 | $33.5K | Buy |
+2,726
| New | +$34.1K | ﹤0.01% | 3546 |
|
|
2021
Q1 | – | Sell |
-5
| Closed | -$34 | – | 4256 |
|
|
2020
Q4 | $34 | Hold |
5
| – | – | ﹤0.01% | 4092 |
|
|
2020
Q3 | $20 | Hold |
5
| – | – | ﹤0.01% | 4158 |
|
|
2020
Q2 | $17 | Hold |
5
| – | – | ﹤0.01% | 4259 |
|
|
2020
Q1 | $11 | Hold |
5
| – | – | ﹤0.01% | 4282 |
|
|
2019
Q4 | $16 | Sell |
5
-159
| -97% | -$637 | ﹤0.01% | 4383 |
|
|
2019
Q3 | $738 | Sell |
164
-44
| -21% | -$220 | ﹤0.01% | 4412 |
|
|
2019
Q2 | $992 | Hold |
208
| – | – | ﹤0.01% | 4369 |
|
|
2019
Q1 | $1.14K | Hold |
208
| – | – | ﹤0.01% | 4147 |
|
|
2018
Q4 | $633 | Buy |
208
+39
| +23% | +$135 | ﹤0.01% | 3980 |
|
|
2018
Q3 | $709 | Hold |
169
| – | – | ﹤0.01% | 4331 |
|
|
2018
Q2 | $653 | Sell |
169
-3,254
| -95% | -$21.6K | ﹤0.01% | 4315 |
|
|
2018
Q1 | $21.7K | Buy |
3,423
+40
| +1% | +$331 | ﹤0.01% | 3908 |
|
|
2017
Q4 | $27.3K | Buy |
3,383
+1,705
| +102% | +$15.9K | ﹤0.01% | 3904 |
|
|
2017
Q3 | $19.2K | Sell |
1,678
-115
| -6% | -$1.21K | ﹤0.01% | 3614 |
|
|
2017
Q2 | $17.5K | Buy |
1,793
+1,484
| +480% | +$30.3K | ﹤0.01% | 3734 |
|
|
2017
Q1 | $7.48K | Sell |
309
-785
| -72% | -$19.6K | ﹤0.01% | 3222 |
|
|
2016
Q4 | $35.1K | Sell |
1,094
-197
| -15% | -$8.4K | ﹤0.01% | 2981 |
|
|
2016
Q3 | $64.5K | Buy |
1,291
+689
| +114% | +$28.6K | ﹤0.01% | 2319 |
|
|
2016
Q2 | $25.5K | Buy |
+602
| New | +$32.8K | ﹤0.01% | 2500 |
|
|
2016
Q1 | – | Sell |
-3,201
| Closed | -$199K | – | 3421 |
|
|
2015
Q4 | $199K | Buy |
3,201
+290
| +10% | +$20.4K | ﹤0.01% | 1928 |
|
|
2015
Q3 | $195K | Buy |
2,911
+1,748
| +150% | +$143K | ﹤0.01% | 1970 |
|
|
2015
Q2 | $113K | Buy |
1,163
+867
| +293% | +$82.5K | ﹤0.01% | 2023 |
|
|
2015
Q1 | $27.6K | Buy |
+296
| New | +$25.2K | ﹤0.01% | 2212 |
|
|
2014
Q4 | – | Sell |
-749
| Closed | -$51.7K | – | 3773 |
|
|
2014
Q3 | $51.7K | Buy |
749
+714
| +2,040% | +$38.2K | ﹤0.01% | 2577 |
|
|
2014
Q2 | $2K | Sell |
35
-124
| -78% | -$6.3K | ﹤0.01% | 3104 |
|
|
2014
Q1 | $5.5K | Hold |
159
| – | – | ﹤0.01% | 2395 |
|
|
2013
Q4 | $6.69K | Sell |
159
-3,151
| -95% | -$91.3K | ﹤0.01% | 2910 |
|
|
2013
Q3 | $98.7K | Sell |
3,310
-1,297
| -28% | -$45.4K | ﹤0.01% | 2420 |
|
|
2013
Q2 | $244K | Buy |
+4,607
| New | +$202K | ﹤0.01% | 2167 |
|
Other funds holding MACK
RA
JC
BNP Paribas Financial Markets's MACK Position: Q2 2024 in Review
BNP Paribas Financial Markets sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 5,077 shares — an estimated $75K sold.
BNP Paribas Financial Markets first reported a position in MACK in Q2 2013 and held it in 33 quarters. The position peaked at $244K in Q2 2013. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- BNP Paribas Financial Markets reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- BNP Paribas Financial Markets sold 5,077 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $75K.
- BNP Paribas Financial Markets first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
- BNP Paribas Financial Markets's Merrimack Pharmaceuticals, Inc. position peaked at $244K in Q2 2013.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2024, filed 13 Aug 2024.